Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06405230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

StatusTerminated
PhasePhase 1/2
Started2025-10-10
View on ClinicalTrials.gov ↗
The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.

Amendment history 3 changes detected by DataLookout

2026-09-04
Trial terminated: Operational challenges
2026-09-04
Final enrollment: 2 participants — 5% of the 40 planned
2026-09-04
Primary completion confirmed: July 2026 (last estimated August 2028)
Trial Details
NCT Number NCT06405230
Lead Sponsor GlaxoSmithKline
Conditions Lung Cancer, Non-Small Cell
Enrollment 2 participants
Start Date 2025-10-10
Primary Completion 2026-07-13 (estimated)
Study Completion 2026-07-13 (estimated)
Updated on ClinicalTrials.gov 2026-09-03